nach oben

Erschienen in:

01.12.2007 | PHASE II STUDIES

Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer

verfasst von: Elisabetta Campagnoli, Isabella Garassino, Armando Santoro, Fabio De Vincenzo, Paolo Andrea Zucali, Giovanni Luca Ceresoli, Fabio Romano Lutman, Marco Alloisio, Hector Josè Soto Parra, Raffaele Cavina

Erschienen in: Investigational New Drugs | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Summary

Cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (NSCLC). Several platinum-based doublets have been tested in phase II/III trials with equivalent results in terms of tumour response and survival. Our study was designed to evaluate activity, tolerability and convenience of alternating intravenous (i.v.) and oral vinorelbine in combination with cisplatin in advanced NSCLC. Forty chemo-naive patients with stage IV or relapsed unresectable disease and good performance status were enrolled to receive i.v. cisplatin 40 mg/m² on days 1 and 2 plus i.v. vinorelbine 25 mg/m² on day 1, every 3 weeks. Oral vinorelbine 60 mg/m² was given at home on day 5, without checking of blood cell count. A total of 175 treatment cycles were delivered. The overall response rate was 30% (one complete, 11 partial responses). Median time to progression and overall survival were 5 and 10 months, respectively. The main toxicity was haematological, with grade 3–4 neutropenia observed in 75% of patients, without febrile neutropenia. Non-haematological toxicity was mild. This schedule of cisplatin and vinorelbine treatment showed a good toxicity profile and an efficacy similar to other standard regimens. Oral vinorelbine could be administered safely at home on day 5.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) For the eastern cooperative oncology group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef

Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer. A South West Oncology Group trial. J Clin Oncol 19:3210–3218PubMed

Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M (2002) For the Italian Lung Cancer Project: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20(21):4285–4291PubMedCrossRef

Depierre A, Chastang CI, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Solal-Celigny P, Badri N, Besenval M (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced NSCLC: a randomized trial. Ann Oncol 5:37–42PubMed

Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S et al. (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin and vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12(2):360–367PubMed

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao M-S, Gandara D, Kesler K, Demmy T, Shepherd F (2005) For the National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators: Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352:2589–2597PubMedCrossRef

The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360CrossRef

Douillard J, Rosell R, Delena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet P-J, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719–727PubMedCrossRef

Gebbia V, Galetta D, Caruso M (2005) Weekly vinorelbine plus cisplatin versus day 1+8 vinorelbine with cisplatin in advanced non-small cell lung cancer: end results of a phase III trial. Lung Cancer 49(Suppl 2):S32CrossRef

10.

Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643–1649PubMedCrossRef

11.

Jassem J, Kosmidis P, Ramlau R, Zarogoulidis K, Novakova L, Breton J, Etienne P-L, Seebacher C, Grivaux M, Ojala A, Aubert D, Lefresne F (2003) Oral vinorelbine in combination with cisplatin: a novel active regimen in advance non-small cell lung cancer. Ann Oncol 14:1634–1639PubMedCrossRef

12.

De Lena M, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J (2005) Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer 48:129–135PubMedCrossRef

13.

Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115PubMed

14.

Nolè F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrida S, Galimberti V, Goldhirsch A, Veronesi U (1999) Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). Ann Oncol 10(8):993–996PubMedCrossRef

15.

Magagnoli M, Balzarotti M, Sarina B, Castagna L, Timofeeva I, Nozza A, Bertuzzi A, Siracusano L, Santoro A (2001) Mobilizing potential of IGEV (ifosfamide, gemcitabine, vinorelbine) chemotherapy in refractory/relapsed Hodgkin’s disease (HD). Bone Marrow Transplant 27(Suppl 1):S269

16.

Zucali PA, Soto Parra HJ, Cavina R, Campagnoli E, Latteri F, Ginanni V, Biancofiore G, Ferrari B, Morenghi E, Santoro A (2003) Results of a dose-findings study with a short-schedule cisplatin (P) and Vinorelbine (V) in non-small cell lung cancer (NSCLC): an attempt to improve feasibility and compliance. Proc Am Soc Clin Oncol 22:2846a

17.

National Cancer Institute (2003) Common toxicity criteria, version 3.0. National Cancer Institute, Bethesda, MD

18.

AJCC (2002) Cancer staging manual, 6th edn. Springer, New York (March)

19.

Fleming TR (1982) One-sample multiple testing procedures for phase II clinical trials. Biometrics 38:143–151PubMedCrossRef

20.

American Society of Clinical Oncology (2004) Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 22:330–353CrossRef

21.

Souquet PJ, Tan EH, Rodriguez Pereira J, Van Klaveren R, Price A, Gatzemeier U, Jaworski M, Burillon JP, Aubert D (2002) GLOB1: a phase III trial comparing the combination of vinorelbine and cisplatin (NP) versus vinorelbine, ifosfamide and cisplatin (NIP) in metastatic non-small cell lung cancer patients (NSCLC). Ann Oncol 13:1853–1861PubMedCrossRef

22.

Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer. J Clin Oncol 16:2459–2465PubMed

23.

Fossella F, Pereira JR, von Pawel J Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016–3024PubMedCrossRef

24.

Gebbia V, Puozzo C (2005) Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 4:1–14CrossRef

25.

Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O’Brien M, Depierre A (2001) A multicenter randomized phase II study of oral versus intravenous vinorelbine in advanced non-small cell lung cancer patients. Ann Oncol 12:1375–1381PubMedCrossRef

26.

O’Brien MER, Szczesna A, Karnicka H, Zatloukal P, Eisen T, Hartman W, Kasan P, Longerey B, Lefresne F (2004) Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. Ann Oncol 15:921–927PubMedCrossRef

27.

Chen Y-M, Yu C-J, Yang C-H, Perng R-P, Tsai C-M, Shih J-F, Cheng A-L, Lefresne F, Barbier M, Pouget J-C, Yang P-C (2007) A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung cancer. Lung Cancer 56:89–95PubMedCrossRef

28.

Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care (2004) Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer 43:223–240PubMedCrossRef

Titel: Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer
verfasst von: Elisabetta Campagnoli
Isabella Garassino
Armando Santoro
Fabio De Vincenzo
Paolo Andrea Zucali
Giovanni Luca Ceresoli
Fabio Romano Lutman
Marco Alloisio
Hector Josè Soto Parra
Raffaele Cavina
Publikationsdatum: 01.12.2007
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 6/2007
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-007-9067-2

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer

Summary

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel

Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors

Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803

Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients

Naphthylnitrobutadienes as pharmacologically active molecules: evaluation of the in vivo antitumour activity

A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie